Crossmark

VEGF-A cis-located SNPs on human chromosome 6 associated with VEGF-A plasma levels and survival in a coronary disease cohort

Published Online: 2025-04-17

Authors

Meza-Alvarado, J. C.

Pilbrow, A. P.

Frampton, C. M.

Cameron, V. A.

Richards, A. M.

Troughton, R. W.

Doughty, R. N.

Page, R. A.

Mallard, B.

Bromhead, C.

Palmer, B. R.
Funding

Funding for this research was provided by:

Heart Foundation of New Zealand (HFNZ1936)

Maurice and Phyllis Paykel Trust (221105)

Health Research Council of New Zealand (HRC 02/152)
License Information

Text and Data Mining valid from 2025-04-17

Version of Record valid from 2025-04-17
More Information

Article History

Received: 2 September 2024

Accepted: 9 April 2025

First Online: 17 April 2025

Declarations

:

: The CDCS study was approved by the New Zealand (NZ) Multi-Region Ethics Committee, retrospectively registered at the Australian New Zealand Clinical Trials Registry (ACTRN12605000431628 on 16 September 2005), and all participating patients provided written, informed consent. The HVOL study was approved by the New Zealand Health and Disability Ethics Committee (Reference CTY/01/05/062) and registered with the Australian New Zealand Clinical Trials Registry (ACTRN1260500448640). All participating patients provided written, informed consent. Both studies conform to the principles outlined in the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46.

: Not applicable – this article does not report an individual participant’s data in any form.

: B.R.P. is a Senior Editorial Board Member of BMC Cardiovascular Disorders.

Document is current